Risk Manag Healthc Policy. 2018;11:117-125. \[[PMC free article: PMC6112781](/pmc/articles/PMC6112781/)\] \[[PubMed: 30197544](https://pubmed.ncbi.nlm.nih.gov/30197544)\] 10. Laäs DJ, Naidoo M. Oral anticoagulants and atrial fibrillation: A South African perspective. S Afr Med J. 2018 Jul 25;108(8):640-646. \[[PubMed: 30182879](https://pubmed.ncbi.nlm.nih.gov/30182879)\] 11. Bai CJ, Madan N, Alshahrani S, Aggarwal NT, Volgman AS. Sex Differences in Atrial Fibrillation-Update on Risk Assessment, Treatment, and Long-Term Risk. Curr Treat Options Cardiovasc Med. 2018 Aug 27;20(10):79. \[[PubMed: 30146677](https://pubmed.ncbi.nlm.nih.gov/30146677)\] 12. Brieger D, Amerena J, Attia JR, Bajorek B, Chan KH, Connell C, Freedman B, Ferguson C, Hall T, Haqqani HM, Hendriks J, Hespe CM, Hung J, Kalman JM, Sanders P, Worthington J, Yan T, Zwar NA. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. Med J Aust. 2018 Oct 15;209(8):356-362. \[[PubMed: 30067936](https://pubmed.ncbi.nlm.nih.gov/30067936)\] 13. Pharithi RB, Ranganathan D, O'Brien J, Egom EE, Burke C, Ryan D, McAuliffe C, Vaughan M, Coughlan T, Morrissey E, McHugh J, Moore D, Collins R. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group. Ir J Med Sci. 2019 Feb;188(1):101-108. \[[PubMed: 29860595](https://pubmed.ncbi.nlm.nih.gov/29860595)\] 14. Dan GA, Iliodromitis K, Scherr D, Marín F, Lenarczyk R, Estner HL, Kostkiewicz M, Dagres N, Lip GYH. Translating guidelines into practice for the management of atrial fibrillation: results of an European Heart Rhythm Association Survey. Europace. 2018 Aug 01;20(8):1382-1387. \[[PubMed: 29893840](https://pubmed.ncbi.nlm.nih.gov/29893840)\] **Disclosure:** Zeid Nesheiwat declares no relevant financial relationships with ineligible companies. **Disclosure:** Amandeep Goyal declares no relevant financial relationships with ineligible companies. **Disclosure:** Mandar Jagtap declares no relevant financial relationships with ineligible companies.